SCHEMBL2172208

SCHEMBL2172208

Nc1cccc2c1-c1ccccc1OP2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 5/20 0.43
PTPRC P08575 1/20 0.39
CSNK1A1 P48729 2/20 0.38
CSNK1D P48730 2/20 0.38
CSNK1G1 Q9HCP0 2/20 0.38
MAOA P21397 2/20 0.38
FGR P09769 1/20 0.38
PIM1 P11309 1/20 0.38
DYRK1A Q13627 1/20 0.38
HIPK2 Q9H2X6 1/20 0.38
ALDH1A1 P00352 4/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
PABPC1 P11940 2/20 0.34
HSPA1A P0DMV8 1/20 0.34
PDK2 Q15119 1/20 0.33
MEN1 O00255 3/20 0.33
POLB P06746 3/20 0.33
KMT2A Q03164 3/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
MAPT P10636 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2172214 0.86 ADORA2A (0.43) ADORA2APTPRCCSNK1A1CSNK1DCSNK1G1
SCHEMBL9080913 0.79 AHR (0.36) ADORA2APDK2SMN1; SMN2HPGDRAB9A
SCHEMBL11222467 0.74 KDM4E (0.34) MAPK1
SCHEMBL18606039 0.70
Naphthoquinone SCHEMBL20378412 0.64 IDO1 (0.50) PTPRCMAOAALDH1A1MEN1POLB
SCHEMBL7389021 0.64 ALDH1A1 (0.67) ADORA2APTPRCCSNK1A1CSNK1DCSNK1G1
SCHEMBL28547340 0.62 PTPRC (0.67) ADORA2APTPRCCSNK1A1CSNK1DCSNK1G1
SCHEMBL1578324 0.62 PTPRC (0.67) ADORA2APTPRCCSNK1A1CSNK1DCSNK1G1
SCHEMBL6760678 0.62 ADORA2A (0.48) ADORA2APTPRCCSNK1A1CSNK1DCSNK1G1
SCHEMBL11256633 0.62 MAOB (0.47) ADORA2APTPRCMAOAALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973191-B2 Method for the production of dibenz[c,e] [1,2]-oxaphosphorin derivatives, amino-dibenz[c,e] [1,2]-oxaphosphorin and also use thereof EMS-PATENT AG (CH) 2011-07-05 US disclosed
US-20100069657-A1 METHOD FOR THE PRODUCTION OF DIBENZ[C,E] [1,2]-OXAPHOSPHORIN DERIVATIVES, AMINO-DIBENZ[C,E] [1,2]-OXAPHOSPHORIN AND ALSO USE THEREOF EMS-PATENT AG (CH) 2010-03-18 US disclosed
CN-101648976-A Method for the production of dibenz[c,e] [1,2]-oxaphosphorin derivatives, amino-dibenz[c,e] [1,2]-oxaphosphorin and also use thereof EMS PATENT AG CH 2010-02-17 CN disclosed
EP-0005441-B1 AMINODIBENZOXAPHOSPHORINES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS STABILISATORS CIBA-GEIGY AG (CH) 1982-05-19 EP disclosed
EP-0005441-A1 Aminodibenzoxaphosphorines, process for their preparation and their use as stabilisators CIBA-GEIGY AG (CH) 1979-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069657-A1 METHOD FOR THE PRODUCTION OF DIBENZ[C,E] [1,2]-OXAPHOSPHORIN DERIVATIVES, AMINO-DIBENZ[C,E] [1,2]-OXAPHOSPHORIN AND ALSO USE THEREOF PFAS, PNP, PNPO ADORA2A 443/4885PTPRC 2350/4885CSNK1A1 1374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.